VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has announced the publication of a peer-reviewed study in Critical Care Medicine demonstrating that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. This finding could significantly impact how clinicians assess and treat sepsis, a condition that affects millions worldwide and carries a high mortality rate.
The study found that Nu.Q NETs H3.1 levels were significantly higher in patients with septic shock compared to those with sepsis alone. Moreover, there was a dose-response relationship between the biomarker levels and the severity of acute kidney injury, suggesting that higher levels correlate with worse outcomes. These results support the potential use of Nu.Q NETs for risk stratification and early intervention, which could be crucial in a condition where time is of the essence.
In addition to the study, the journal also published an independent editorial examining H3.1 nucleosomes as a potential marker of NET-mediated organ injury. This editorial adds further credibility to the biomarker's relevance in understanding the pathophysiology of sepsis.
Volition believes that the Nu.Q NETs test could help clinicians anticipate disease progression, guide treatment decisions, and monitor patients over time across acute and chronic conditions. The company cites a total addressable market of $2.8 billion for this technology, indicating substantial commercial potential. The latest findings add to previously published evidence supporting the clinical utility of Nu.Q NETs.
Dr Andrew Retter, Medical Consultant at Volition, emphasized the potential impact: "Introducing Nu.Q NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors." This statement underscores the broader implications for patient care and healthcare systems.
For business and technology leaders, this development highlights the growing role of advanced diagnostics in precision medicine. The ability to predict outcomes and tailor interventions based on biomarker levels could lead to more efficient use of healthcare resources, reduced hospital stays, and improved patient outcomes. It also represents a significant opportunity in the diagnostics market, potentially influencing investment decisions and partnerships in the biotech sector.
Volition is focused on advancing the science of epigenetics and developing simple, cost-effective blood tests for early detection and monitoring of diseases. The company's research and development activities are centered in Belgium, with an innovation laboratory in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/. The full press release can be viewed at https://ibn.fm/RErhc.
